Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
When treating adenocarinoma of the pancreas to 75 Gy in 25 fractions, what dose constraints do you use for small bowel, large bowel, and stomach?
What are your fields? Do you treat nodes electively?
Answer from: Radiation Oncologist at Academic Institution
Planning Volumes Definition Doses by Fractionation Scheme 15-Fraction 25-Fraction Microscopic Extension PTV CTV + 5mm (CTV = GTV + 1cm + CA, SMA, +/- porta hepatis, +/- splenic hilum basins) 37.5Gy/15 45Gy/25...
Sign in or Register to read more
4382
Related Questions
Given the results of ESOPEC from ASCO 2024, for which patients with resectable esophageal adenocarcinoma would you favor neoadjuvant chemoradiation?
When treating a bulky squamous cell carcinoma of the anal canal, do you try to limit the dose to the external anal sphincter to any particular number to reduce the risk of chronic fecal incontinence?
Is it safe to treat the stomach to a definitive dose if the patient has a G-tube/PEG in place?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
Would you offer inguinal nodal RT to a patient with anal SCC (pT1N1a, + inguinal node) following APR in the setting of prior prostate + pelvic nodal radiation?
How would you approach treatment of a patient with adenocarcinoma of unknown primary only found in a left supraclavicular lymph node?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
When would you opt to manage anal squamous cell carcinoma, HPV+ with surveillance vs adjuvant treatment following a trans-anal excision?
How was treatment response assessed on the PROSPECT trial?
Would you recommend adjuvant radiotherapy in addition to chemotherapy in gastric adenocarcinoma s/p gastrectomy with a distal positive resection margin?